Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.97 -0.19 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Why Are Apellis Pharmaceuticals Shares Falling Today? ↗
 
Via Benzinga
News headline image
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio ↗
Apellis long said it wouldn't wait for 24-month data for its eye drug. Apellis was wrong. 
Via Investor's Business Daily
News headline image
Why Starbucks Shares Are Trading Higher; Here Are 43 Stocks Moving Premarket ↗
Gainers Sentage Holdings Inc. (NASDAQ: SNTG) shares rose 67.7% to $5.10 in pre-market trading after jumping 24% on Thursday. 
Via Benzinga
News headline image
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Where Apellis Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings: 
Via Benzinga
News headline image
Apellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two Years ↗
 
Via Benzinga
News headline image
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH) 
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Where Apellis Pharmaceuticals Stands With Analysts ↗
  Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings: 
Via Benzinga
News headline image
7 Analysts Have This to Say About Apellis Pharmaceuticals ↗
Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. 
Via MarketBeat
Topics Stocks
News headline image
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today ↗
Both companies presented data at the American Academy of Ophthalmology meeting. 
Via Investor's Business Daily
News headline image
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday ↗
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per... 
Via Benzinga
News headline image
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session ↗
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share. 
Via Benzinga
News headline image
Investigator Says Apellis' Lead Product Shows 'First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth' ↗
 
Via Benzinga
News headline image
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗
Stifel has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and raise its price target from $60.00 to $65.00. Shares of Apellis Pharmaceuticals are trading up 2.69% over the... 
Via Benzinga
News headline image
Moderna To $165? Plus This Analyst Cuts PT On FedEx ↗
Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ: MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to... 
Via Benzinga
News headline image
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday ↗
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company. 
Via Benzinga
News headline image
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday ↗
U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study ↗
Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in... 
Via Benzinga
News headline image
7 Cheap Biotech Stocks to Buy Now ↗
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
News headline image
Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary ↗
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness... 
Via Benzinga
News headline image
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday ↗
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.